Investor sentiment on Teva Pharma's (NYSE:TEVA) story continues to improve, according to analysts at BofA, who reiterated a Buy rating and $13 per share price target on the stock on Monday.
The analysts explained to investors in a note that the firm hosted investor meetings with TEVA management, CEO Richard Francis, and CMO Eric Hughes last week.
"Overall, we felt investor sentiment on TEVA’s story continues to improve with a focus on continued execution and ‘24E validation of the ‘Pivot to Growth’ strategy (where EBITDA growth will be key)," the analysts wrote.
"We came away from the meetings more confident in TEVA’s ability to grow 2024+ EBITDA (BofA: $4.75bn or +5% vs. cons $4.63bn) on the strength of CNS brands, better margins (mix) and the trajectory of global generics."
Furthermore, BofA feels continued execution and resolution of small/manageable risk factors should expand TEVA’s investor appeal.
TEVA shares are up more than 1% at $8.80 per share at the time of writing on Monday. The stock is down around 4% in 2023.